Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-VSV G/Glycoprotein G Antibody (VI22)

Catalog #:   RVV09814 Specific References (54) DATASHEET
Host species: Human
Isotype: IgG1, kappa
Applications: ELISA
Expression system: Mammalian Cells
Overview

Catalog No.

RVV09814

Expression system

Mammalian Cells

Species reactivity

Vesicular stomatitis Indiana virus (strain Mudd-Summers) (VSIV)

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

G, Glycoprotein G

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P0C2X0

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

VI22

Data Image
  • SDS-PAGE
    SDS PAGE for VSV G/Glycoprotein G Antibody
References

Genome-based reclassification of Azospirillum brasilense Sp245 as the type strain of Azospirillum baldaniorum sp. nov. PMID: 33064068

Surgery and radiotherapy in the treatment of cutaneous melanoma. PMID: 19617294

Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. PMID: 17591826

Influence of Er:YAG laser irradiation distance on the bond strength of a restorative system to enamel. PMID: 16153764

A New Vaccine Candidate Expressing JUNV GP1-GP2 Against Argentine Hemorrhagic Fever Based on Baculovirus Surface Display., PMID:40514553

Scalable Production of Recombinant Vesicular Stomatitis Virus Pseudoparticles Using HEK293 Suspension Cultures., PMID:40462709

Designed miniproteins potently inhibit and protect against MERS-CoV., PMID:40450691

Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge., PMID:40447644

Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review., PMID:40432133

Evaluating Neutralizing Antibodies in Hantavirus-Infected Patients Using Authentic Virus and Recombinant Vesicular Stomatitis Virus Systems., PMID:40431735

Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies., PMID:40403696

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever., PMID:40367816

Comparison of the induction of neutralizing antibodies against Bas congo virus using several vaccine modalities., PMID:40348847

Establishment of a pseudovirus neutralization assay for TGEV., PMID:40276514

The Pseudotyped Replication-Deficient VSV with Spike from PEDV Induces Neutralizing Antibody Against PEDV., PMID:40266086

Simian Immunodeficiency Virus-Based Virus-like Particles Are an Efficient Tool to Induce Persistent Anti-SARS-CoV-2 Spike Neutralizing Antibodies and Specific T Cells in Mice., PMID:40266067

Single-dose VSV-Sudan virus vaccine protects from lethal Sudan virus infection within one week: a challenge study in macaques., PMID:40196593

Membrane-targeted immunogenic compositions using exosome mimetic approach for vaccine development against SARS-CoV-2 and other pathogens., PMID:40157987

Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials., PMID:40157130

A VSV-based oral rabies vaccine was sentineled by Peyer's patches and induced a timely and durable immune response., PMID:40022445

Tim-3 promotes viral infection by suppressing the USP25-TRAF3-IRF7 signaling pathway., PMID:39946759

Standardization, validation, and comparative evaluation of a convenient surrogate recombinant vesicular stomatitis virus plaque reduction test for quantification of Hantaan orthohantavirus (HTNV) neutralizing antibodies., PMID:39923054

Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses., PMID:39922192

Development and application of a high-titer VSV-based HCoV-NL63 pseudovirus system via C-terminal 14 amino acid truncation of spike., PMID:39922054

Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus., PMID:39879304

Short-term oral exposure to nanoplastics does not significantly impact the antiviral immune response of the mouse., PMID:39854993

A hTfR1 Receptor-Specific VHH Antibody Neutralizes Pseudoviruses Expressing Glycoproteins from Junín and Machupo Viruses., PMID:39772257

PD1-Targeted Transgene Delivery to Treg Cells., PMID:39772246

A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories., PMID:39772242

Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus., PMID:39772063

A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease., PMID:39745141

Vesicular Stomatitis Virus Transmission Dynamics Within Its Endemic Range in Chiapas, Mexico., PMID:39599856

Quantification of Neutralizing Antibodies in Serum Using VSV-MARV-GFP., PMID:39585633

Serosurvey of Arboviruses in Free-Ranging Mantled Howler Monkeys (Alouatta palliata) in Costa Rica., PMID:39573905

Assessment of Single-Cycle M-Protein Mutated Vesicular Stomatitis Virus as a Safe and Immunogenic Mucosal Vaccine Platform for SARS-CoV-2 Immunogen Delivery., PMID:39526809

Avian TRIM13 attenuates antiviral innate immunity by targeting MAVS for autophagic degradation., PMID:39508267

Cellular NONO protein binds to the flavivirus replication complex and promotes positive-strand RNA synthesis., PMID:39499073

Intranasal Prime-Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection., PMID:39460356

Improved efficacy of SARS-CoV-2 isolation from COVID-19 clinical specimens using VeroE6 cells overexpressing TMPRSS2 and human ACE2., PMID:39438626

Protocol for constructing and characterizing recombinant vectored vaccines for rabies virus., PMID:39423123

Development of pseudotyped VSV-SARS-CoV-2 spike variants for the assessment of neutralizing antibodies., PMID:39411978

Enhancing the Efficacy of Breast Cancer Immunotherapy Using a Smac-Armed Oncolytic Virus., PMID:39409870

Immunogenicity and Neutralization of Recombinant Vaccine Candidates Expressing F and G Glycoproteins against Nipah Virus., PMID:39340029

The Autonomous Fusion Activity of Human Cytomegalovirus Glycoprotein B Is Regulated by Its Carboxy-Terminal Domain., PMID:39339958

Bats generate lower affinity but higher diversity antibody responses than those of mice, but pathogen-binding capacity increases if protein is restricted in their diet., PMID:39316608

CD40 stimulation activates CD8+ T cells and controls HBV in CD4-depleted mice., PMID:39282227

Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies., PMID:39252967

Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques., PMID:39205155

Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model., PMID:39126087

Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon., PMID:39121969

Mosaic neuraminidase-based vaccine induces antigen-specific T cell responses against homologous and heterologous influenza viruses., PMID:39117282

Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model., PMID:39116029

Surveillance of Feral Swine (Sus scrofa) in the Western USA for Antibodies to Vesicular Stomatitis Virus, 2013-21., PMID:39074817

Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2., PMID:38933606

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-VSV G/Glycoprotein G Antibody (VI22) [RVV09814]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only